Avobis Bio Receives FDA RMAT Desingation for AVB-114
FDA Grants RMAT Designation to Avobis Bio’s Implantable Cell Therapy AVB-114 for Crohn’s Perianal Fistulas – Designation sets the stage for intensive phase III trial planning with FDA – NEWARK, DE, Oct 3, 2025 /PRNewswire/ — Avobis Bio LLC, a clinical stage company developing implantable cell therapies, announced today that the U.S. Food and Drug […]
Avobis Bio to Present at American College of Gastroenterology’s 2025 Annual Scientific Meeting
Avobis Bio is pleased to announce that the primary analysis results of the phase II prospective, randomized STOMP-II clinical trial will be presented at ACG’s 2025 Annual Scientific Meeting. The STOMP-II trial is assessing AVB-114, Avobis Bio’s lead implantable cell therapy candidate, against the standard of care for the treatment of Crohn’s Disease perianal fistulas. […]
Avobis Bio to Present at 2025 Cell and Gene Meeting on the Mesa
Tiffany Brown, PhD, Chief Executive Officer, will be presenting at the Alliance for Regenerative Medicine’s 2025 Cell and Gene Meeting on the Mesa. Please join us on Monday, October 6 at 3:15pm in FLW Ballroom G to hear about the exciting progress being made at Avobis Bio. Meeting on the Mesa is the sector’s foremost […]
STOMP-II Primary Analysis Complete
Avobis Bio Completes Primary Analysis of STOMP-II Randomized Clinical Trial of AVB-114 in Crohn’s Perianal Fistulas – Analysis leads to FDA RMAT submission and late-breaking abstract for implantable cell therapy – NEWARK, DE, Aug 7, 2025 /PRNewswire/ — Avobis Bio LLC, a clinical stage company developing implantable cell therapies, announced today that primary analysis […]
Avobis Bio to Present at the 2025 BIO International Convention
Tiffany Brown, PhD, Chief Executive Officer, will be presenting at the 2025 BIO International Convention in Boston, MA. Please join us for the presentation on Wednesday June 18, 2025 at 12:15pm in Room 153A. The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 […]
Avobis Bio Presents at LSI USA 2025 Summit
Tiffany Brown, PhD, Chief Executive Officer, presented at the LSI USA 2025 Summit in Dana Point, CA on March 18, 2025. LSI USA is medtech’s most anticipated event of the year. It brings together executives from emerging companies, venture capital and private equity firms, family offices, global strategics, professional service providers, and more. 1,600 people […]
Avobis Bio to present at the LSI USA 2025 Summit
Tiffany Brown, PhD, Chief Executive Officer, will be presenting at the LSI 2025 Summit in Dana Point, CA on March 18, 2025 at 2:30pm. LSI USA is medtech’s most anticipated event of the year. It brings together executives from emerging companies, venture capital and private equity firms, family offices, global strategics, professional service providers, and […]
Avobis Bio to present at Investival Showcase USA 2025
Tiffany Brown, PhD, Chief Executive Officer, will be presenting at the Investival Showcase USA in Miami, Florida on March 10, 2025 at 3:00pm. See here for more information. Investival Showcase USA is North America’s premier biotech, medtech, and digital health networking event that connects innovators with investors.
FDA Grants Fast Track Designation for AVB-114
Avobis Bio Receives FDA Fast Track Designation for AVB-114 Implantable Cell Therapy for Crohn’s Perianal Fistulas – Only implantable cell therapy for Crohn’s perianal fistulas with FDA IND clearance and Fast Track designation – NEWARK, DE, February 27, 2025 /PRNewswire/ – Avobis Bio LLC, a clinical stage company developing implantable cell therapies, announced today that […]
Avobis Bio presents at the 17th Annual Biotech Showcase
Tiffany Brown, PhD, Chief Executive Officer, presented at the 17th Annual Biotech Showcase in San Francisco, CA on January 14, 2025. The company presentation can be viewed here. Biotech Showcase is the premier event that kicks off the new year by bringing together a dynamic community of innovators, investors, and industry leaders. The 2025 showcase had […]
